Norrby R
Scand J Infect Dis Suppl. 1978(13):83-7.
Since the introduction of cephalothin and cephaloridine as the first parenteral cephalosporins and cephalexin as the first member of the group which is absorbed from the gastrointestinal tract, several new cephalosporin derivatives have been developed. Most of these have no major advantages over cephalothin, cephaloridine or cephalexin. Increased knowledge about the importance of beta-lactamases for bacterial resistance against beta-lactam antibiotics has focused interest on development of drugs with increased resistance to degradation by these enzymes. Among the caphalosporins, cefamandole and cefuroxime have been found to be markedly more active against beta-lactamase producing Gram-negative bacteria. A new group of beta-lactam antibiotics, the cephamycins, have been introduced with cefoxitin as the first clinically useful member. Cefoxitin has the spectrum of a beta-lactamase-resistant cephalosporin and is also active against Bacteroides fragilis. The review concentrates on the antibacterial spectrum of these three new antibiotics and on their clinical efficacy.
自从头孢噻吩和头孢噻啶作为第一代注射用头孢菌素以及头孢氨苄作为第一代可从胃肠道吸收的头孢菌素问世以来,已研发出多种新的头孢菌素衍生物。其中大多数与头孢噻吩、头孢噻啶或头孢氨苄相比并无显著优势。随着人们对β-内酰胺酶在细菌对β-内酰胺类抗生素耐药性方面重要性的认识不断增加,注意力集中在了开发对这些酶降解具有更高耐药性的药物上。在头孢菌素中,已发现头孢孟多和头孢呋辛对产β-内酰胺酶的革兰氏阴性菌具有明显更高的活性。一类新的β-内酰胺抗生素——头霉素类已问世,头孢西丁是首个具有临床实用性的成员。头孢西丁具有对β-内酰胺酶耐药的头孢菌素的抗菌谱,并且对脆弱拟杆菌也有活性。本综述着重于这三种新抗生素的抗菌谱及其临床疗效。